Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Anti-inflammatory coxib medications inhibit aspirin's protective qualities

A new study conducted at Ben-Gurion University of the Negev (BGU) reveals that Celebrex and other anti-inflammatory coxib medications may counter the positive effects of aspirin in preventing blood clots.

24 Dec 2009

Protective benefits of Alzheimer's and cancer may lead to new diagnostic treatments

People who have Alzheimer's disease may be less likely to develop cancer, and people who have cancer may be less likely to develop Alzheimer's disease, according to a new study published in the December 23, 2009, online issue of Neurology®, the medical journal of the American Academy of Neurology.

23 Dec 2009

CEO Cancer Gold Standard accreditation for Aldagen

Aldagen, Inc. has received CEO Cancer Gold Standard™ accreditation, recognizing the company’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

23 Dec 2009

Beta blockers may increase risk of anemia-induced adverse cardiovascular events

Routinely used to treat patients for heart attack or high blood pressure, beta blockers are known for their role in helping to protect the heart. A new study in the January issue of the journal Anesthesiology looks at the effects of beta blockers on surgical outcomes, revealing that the cardioprotective effects of the medication could be compromised by acute surgical anemia.

23 Dec 2009

UMHC activates Philips VISICU eICU Program to care for critically ill patients

University of Mississippi Health Care (UMHC) announced today its activation of the Philips VISICU eICU® Program to enhance care of the critically ill in rural communities of Mississippi. As the first health system in the region to implement the eICU Program, UMHC will serve as the lead resource for critical care across Mississippi.

23 Dec 2009

Heart and Stroke Foundation urges government to regulate trans fats in Canada's food supply

The Heart and Stroke Foundation calls on the federal government to live up to the commitment made two years ago to regulate trans fats in Canada's food supply, based on Health Canada's final set of monitoring results released today.

23 Dec 2009

Darbepoetin alfa does not reduce cardiovascular problem in anemic patients on dialysis

An international study authored by a UT Southwestern Medical Center researcher has concluded that the anemia drug darbepoetin alfa works no better than a placebo in several other applications previously thought to be promising.

22 Dec 2009

Shire submits REPLAGAL BLA with the FDA

Shire plc , the global specialty biopharmaceutical company, today announced that it has submitted a BLA with the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease. REPLAGAL first received marketing authorization in the European Union in 2001, and is approved for the treatment of Fabry disease in 45 countries.

22 Dec 2009

Specialists On Call achieves telemedicine milestone

Specialists On Call, Inc. (SOC), announced today that it recently delivered its 10,000th emergency teleneurology consultation since the company's inception. This telemedicine milestone is an unprecedented achievement and expands SOC's leadership position as the largest private emergency teleneurology provider in the country.

22 Dec 2009

Halifax Health Systems receives 2009 InfoWorld 100 Award

Meru Networks, Inc., a pioneer in 802.11n enterprise networking, announced today that its customer Halifax Health Systems, a facilitator of specialized healthcare services in East Central Florida, received an InfoWorld 100 Award for deploying one of the 100 best information technology (IT) projects of 2009. Halifax’s wireless LAN (WLAN) infrastructure employs Meru Networks high-performance 802.11n technology as the foundation for wireless connectivity in their new 500,000 square foot state-of-the-art medical facility in Daytona Beach, Florida.

22 Dec 2009

AAPM dispels common myths about CT scans

A panel of experts at the American Association of Physicists in Medicine (AAPM) has issued a statement calling for an open discussion of the facts about radiation hazards from computed tomography (CT) scanning in light of recent public concerns and news reports about radiation dose.

22 Dec 2009

Effectiveness of VSEL stem cells in regenerative medicine demonstrated at the ASH meeting

NeoStem, Inc. (NYSE Amex: NBS), which is a leading provider of pre-disease adult stem cell collection, processing and long-term storage services, and holds the exclusive, worldwide license to VSEL(TM) technology that uses very small embryonic-like stem cells isolated from peripheral blood, announced today that five posters and two oral presentations at the prestigious American Society of Hematology (ASH) Annual Meeting in New Orleans in early December demonstrated the basic cellular mechanisms of very small embryonic-like stem cells.

21 Dec 2009

Headache on rare occasions can be a warning sign of potentially serious disorder

Headaches are extremely common. Almost everyone has experienced a severe headache at least once in his or her lifetime. In most cases, headaches are minor nuisances that resolve within a short time. However, a headache can on rare occasions be the warning sign of a potentially serious disorder that requires immediate medical attention.

19 Dec 2009

Study provides new definition on dyslexia

Contrary to popular belief, some very smart, accomplished people cannot read well. This unexpected difficulty in reading in relation to intelligence, education and professional status is called dyslexia, and researchers at Yale School of Medicine and University of California Davis, have presented new data that explain how otherwise bright and intelligent people struggle to read.

18 Dec 2009

JDRF to work with Johnson & Johnson to develop drug targets and pathways for treating diabetes

The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, said today that it will begin working with The Johnson & Johnson Corporate Office of Science and Technology, and its affiliates, to speed the development of drug targets and pathways to promote the survival and function of insulin-producing cells in people who have diabetes.

18 Dec 2009

Unigene Laboratories selects UGP281 lead peptide from obesity program for development

Unigene Laboratories, Inc. (http://www.unigene.com) announced today that it has selected a lead peptide compound, designated UGP281, from its obesity program for development.

18 Dec 2009

Avecia Biologics to be acquired by Merck

Merck & Co. Inc., (operating in the United Kingdom as MSD) and Avecia Investments Limited today announced that they have entered into a definitive agreement by which Merck will acquire the biologics business of the Avecia group through a Merck affiliate (Merck Sharp & Dohme (Holdings) Limited or "MSD"). Avecia Biologics is a contract manufacturing organization with specific expertise in microbial-derived biologics. Financial details of the transaction were not disclosed.

17 Dec 2009

Neurologist performs catheter procedure on stroke patient

Most strokes are caused by blood clots in brain vessels. Brain cells die when deprived of blood and oxygen. But if a patient gets to the hospital in time, fast treatment often can restore blood flow and minimize damage.

17 Dec 2009

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence.

17 Dec 2009

Discovery of common single-letter variant in SNP links parental origin to risk of T2D

Scientists at deCODE genetics, Inc. publish in the journal Nature the discovery of a version of a common single-letter variant in the sequence of the human genome (SNP) with a major impact on susceptibility to type 2 diabetes (T2D).

17 Dec 2009

Stroke News and Research

Further Reading

Anti-inflammatory coxib medications inhibit aspirin's protective qualities

Protective benefits of Alzheimer's and cancer may lead to new diagnostic treatments

CEO Cancer Gold Standard accreditation for Aldagen

Beta blockers may increase risk of anemia-induced adverse cardiovascular events

UMHC activates Philips VISICU eICU Program to care for critically ill patients

Heart and Stroke Foundation urges government to regulate trans fats in Canada's food supply

Darbepoetin alfa does not reduce cardiovascular problem in anemic patients on dialysis

Shire submits REPLAGAL BLA with the FDA

Specialists On Call achieves telemedicine milestone

Halifax Health Systems receives 2009 InfoWorld 100 Award

AAPM dispels common myths about CT scans

Effectiveness of VSEL stem cells in regenerative medicine demonstrated at the ASH meeting

Headache on rare occasions can be a warning sign of potentially serious disorder

Study provides new definition on dyslexia

JDRF to work with Johnson & Johnson to develop drug targets and pathways for treating diabetes

Unigene Laboratories selects UGP281 lead peptide from obesity program for development

Avecia Biologics to be acquired by Merck

Neurologist performs catheter procedure on stroke patient

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Discovery of common single-letter variant in SNP links parental origin to risk of T2D

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News